Sign inJoin waitlistJoin the waitlist

Peter Greenberg

Acting Chief, Medical Service, VA Palo Alto Health Care System (1978 · Stanford Health Care

Credentials: · · · ·

History

Medical Service Division · Stanford Health Care
Present
Stanford MDS Center · Stanford Health Care
Present
Stanford Health Care
Present

Stanford University Hematology and Oncology Fellowship (1971) CA
1968–1971
Stanford University
1965–1968
Barnes and Allied Hospitals/Washington University School of Med (1964) MO
1963–1964
George Washington Univ Sch of Med
1959–1963

Research

International scoring system for evaluating prognosis in myelodysplastic syndromes
Blood · 1997 · First of 15 authors · 3,502 citations
Revised international prognostic scoring system for myelodysplastic syndromes
Blood · 2012 · First of 34 authors · Corresponding · 2,603 citations
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Blood · 2006 · 1,429 citations

John Bennett
38 papers
Guillermo Garcia-Manero
30 papers
Mikkael Sekeres
23 papers
Richard Stone
19 papers
Joachim Deeg
17 papers
MT
Martin Tallman
17 papers
RK
Rami Komrokji
17 papers
SG
Steven Gore
17 papers
AL
Alan List
16 papers
AD
Amy DeZern
16 papers
Michael Savona
16 papers
Rafael Bejar
16 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $281.5K · Stanford University
1997–2008
Cellular and Humoral Modulation of Hemopoiesis
National Cancer Institute · R01
Contact PI · $750.7K · Stanford University
1984–1991

Clinical trials

Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk
Principal investigator · Completed
Peter L Greenberg
2009–2011
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Principal investigator · Completed · Phase 2
Traws Pharma, Inc.
2009–2013
A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
Principal investigator · Completed · Phase 1, Phase 2
Peter L Greenberg
2002–2008
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)
2000–2017